Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
作者信息
Vestbo Jørgen
机构信息
Division of Infection, Immunity, and Respiratory MedicineThe University of ManchesterManchester, United Kingdomand.
North West Lung CentreManchester University NHS Foundation TrustManchester, United Kingdom.
出版信息
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463-1464. doi: 10.1164/rccm.202003-0622ED.
Abstract
摘要
相似文献
1
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?慢性阻塞性肺疾病的固定三联疗法与生存率。是活得更好、更久，还是两者兼得？
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463-1464. doi: 10.1164/rccm.202003-0622ED.
2
Reply to López-Campos : Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.回复洛佩斯 - 坎波斯：慢性阻塞性肺疾病的三联疗法试验：死亡率效应的方法学考量
Am J Respir Crit Care Med. 2021 Apr 1;203(7):928-929. doi: 10.1164/rccm.202012-4494LE.
3
Mortality in IMPACT: Confounded by Asthma?IMPACT研究中的死亡率：受哮喘影响而混淆？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):772-773. doi: 10.1164/rccm.202004-1159LE.
4
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?对苏伊萨的回复：IMPACT研究中的死亡率：被哮喘混淆了？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):773-774. doi: 10.1164/rccm.202004-1399LE.
5
[Once daily with a powder inhaler].
MMW Fortschr Med. 2015 Jun 11;157(11):66. doi: 10.1007/s15006-015-3225-9.
6
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.FULFIL 试验：慢性阻塞性肺疾病患者的每日一次三联疗法。
Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.
7
Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.氟替卡松乌美溴铵维兰特罗三联治疗慢性阻塞性肺疾病。
Expert Rev Respir Med. 2018 Dec;12(12):997-1005. doi: 10.1080/17476348.2018.1548936. Epub 2018 Nov 28.
8
[Fixed combination of long-acting bronchodilators in COPD].[慢性阻塞性肺疾病中长效支气管扩张剂的固定复方制剂]
Praxis (Bern 1994). 2015 Oct 28;104(22):1221.
9
Fluticasone furoate and vilanterol for COPD.糠酸氟替卡松和维兰特罗用于慢性阻塞性肺疾病
Lancet Respir Med. 2013 Jul;1(5):e21. doi: 10.1016/S2213-2600(13)70100-0. Epub 2013 Jul 8.
10
Fluticasone furoate and vilanterol for COPD - authors' reply.糠酸氟替卡松和维兰特罗用于慢性阻塞性肺疾病——作者回复
Lancet Respir Med. 2013 Jul;1(5):e21-2. doi: 10.1016/S2213-2600(13)70125-5. Epub 2013 Jul 8.
引用本文的文献
1
Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease - nationwide development from 1998 to 2018.慢性阻塞性肺疾病患者吸入性糖皮质激素治疗与肺炎——1998年至2018年全国性发展情况
Eur Clin Respir J. 2024 May 29;11(1):2359768. doi: 10.1080/20018525.2024.2359768. eCollection 2024.
2
Effects of cigarette smoke exposure on pulmonary physiology, muscle strength and exercise capacity in a retrospective cohort with 30,000 subjects.吸烟对 30000 名研究对象的肺生理、肌肉力量和运动能力的回顾性队列研究结果
PLoS One. 2021 Jun 24;16(6):e0250957. doi: 10.1371/journal.pone.0250957. eCollection 2021.
3
Considerations for and Mechanisms of Adjunct Therapy in COPD.慢性阻塞性肺疾病辅助治疗的考量因素及机制
J Clin Med. 2021 Mar 16;10(6):1225. doi: 10.3390/jcm10061225.
本文引用的文献
1
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.氟替卡松维兰特罗/乌美溴铵粉雾剂降低慢性阻塞性肺疾病患者全因死亡率。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.
2
The Magic of Randomization versus the Myth of Real-World Evidence.随机化的魔力与真实世界证据的神话
N Engl J Med. 2020 Feb 13;382(7):674-678. doi: 10.1056/NEJMsb1901642.
3
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.血液嗜酸性粒细胞与慢性阻塞性肺疾病三联和双联治疗反应：IMPACT 试验分析。
Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.
4
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.全球慢性阻塞性肺疾病诊断、管理和预防策略：GOLD 科学委员会报告 2019.
Eur Respir J. 2019 May 18;53(5). doi: 10.1183/13993003.00164-2019. Print 2019 May.
5
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.入组前用药对SUMMIT研究临床结局的影响。
ERJ Open Res. 2019 Feb 25;5(1). doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.
6
Inhaled corticosteroid containing combinations and mortality in COPD.慢性阻塞性肺疾病中含吸入性皮质类固醇的联合用药与死亡率
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01230-2018. Print 2018 Dec.
7
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.COPD 患者每日一次单吸入器三联与双联治疗。
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
8
Effectiveness efficacy trials in COPD: how study design influences outcomes and applicability.COPD 疗效试验：研究设计如何影响结果和适用性。
Eur Respir J. 2018 Feb 21;51(2). doi: 10.1183/13993003.01531-2017. Print 2018 Feb.
9
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.一项 COPD 单次三联疗法的 III 期随机对照试验：IMPACT 方案。
Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.
10
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.氟替卡松酯和维兰特罗与心血管风险升高的慢性阻塞性肺疾病患者的生存关系（SUMMIT）：一项双盲随机对照试验。
Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.
Zotero 插件